StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-22 | $53.81 | $54.50 | +1.28% | 3.1M |
| 05-26 | $54.72 | $53.86 | -1.57% | 2.8M |
| 05-27 | $53.84 | $53.97 | +0.24% | 3.1M |
| 05-28 | $53.70 | $54.48 | +1.45% | 3.1M |
| 05-29 | $54.48 | $55.76 | +2.35% | 18.0M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $630.58M | $2.38B | $1.76B | $1.15B |
Operating Income | $563.04M | $1.56B | $1.17B | $743.98M |
Net Income | $294.69M | $770.95M | $556.74M | $268.52M |
EPS (Diluted) | $0.67 | $1.78 | $1.28 | $0.62 |
Total Assets | $19.82B | $19.62B | $19.35B | $18.32B |
Total Liabilities | $9.88B | $9.91B | $9.73B | $8.82B |
Cash & Equivalents | $586.39M | $618.70M | $938.94M | $631.91M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 556.84M | 564.46M | 566.75M | 570.16M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.